Sector News

Seqirus to spend $140M, add 120 jobs in N.C. flu vaccine plant expansion

November 21, 2018
Life sciences

Seqirus has big plans for its cell-based flu vaccine franchise, and after a scale-up to reach 20 million doses this year, the company still needs more capacity. The vaccine maker has unveiled a $140 million expansion to its Holly Springs, North Carolina, manufacturing plant as it aims to take the vaccine global.

The expansion will add 120 jobs to the site that Seqirus’ parent company, CSL, acquired from Novartis in 2015, allowing it to create the flu vaccine specialist. Six hundred employees already work there.

As traditional flu vaccines have faced efficacy questions over the last year, alternatives have garnered increasing attention. Officials in the U.K. previously endorsed Seqirus’ adjuvanted Fluad for adults over 65, and European experts last month recommended cell-based Flucelvax for approval. If Seqirus secures that approval by the end of year as expected, the company would market the shot as Flucelvax Tetra in Europe starting in the 2019-2020 flu season.

When CSL purchased Novartis’ vaccines outfit and formed Seqirus back in 2015, the Holly Springs plant was making just 3 million doses of cell-based vaccine per year. This flu season, Seqirus plans to produce and distribute 20 million doses of Flucelvax in the U.S. and the company has said it has capacity for 40 million doses next year to support new launches. The expansion, which is expected to be complete by 2020, will further boost capacity for global markets.

Cell-based vaccines have garnered increasing interest after traditional egg-based flu shots faced efficacy questions last season. Last year, flu vaccines were 40% effective overall in the U.S., according to the CDC. In October, Seqirus presented an analysis of data from 12 flu seasons showing that H3N2 flu vaccine strains derived from cells better matched circulating strains than the vaccine strains made in eggs.

At the time, Seqirus president Gordon Naylor said egg-based vaccines remain the “backbone of the industry,” but he envisions newer alternatives gaining steam and potentially taking over the market. That would depend on continued positive efficacy data, increased manufacturing scale and support from the medical community, Naylor said.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach